PD ‐1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study

ConclusionRetifanlimab, INCB001158, and their combination had acceptable safety profiles. Promising retifanlimab antitumor activity warrants further investigation in Japanese patients.

Source: Cancer Medicine - April 23, 2024 Category: Cancer & Oncology Authors: Yasutoshi Kuboki, Takafumi Koyama, Nobuaki Matsubara, Yoichi Naito, Shunsuke Kondo, Kenichi Harano, Kan Yonemori, Kiyotaka Yoh, Yuan Gu, Tetsuya Mita, Xuejun Chen, Eiji Ueda, Noboru Yamamoto, Toshihiko Doi, Toshio Shimizu Tags: RESEARCH ARTICLE Source Type: research